Re-engineering a neuroprotective, clinical drug as a procognitive agent with high in vivo potency and with GABA(A) potentiating activity for use in dementia

BACKGROUND: Synaptic dysfunction is a key event in pathogenesis of neurodegenerative diseases such as Alzheimer’s disease (AD) where synapse loss pathologically correlates with cognitive decline and dementia. Although evidence suggests that aberrant protein production and aggregation are the causati...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Jia, Lee, Sue H., VandeVrede, Lawren, Qin, Zhihui, Piyankarage, Sujeewa, Tavassoli, Ehsan, Asghodom, Rezene T., Aissa, Manel Ben, Fà, Mauro, Arancio, Ottavio, Yue, Lan, Pepperberg, David R., Thatcher, Gregory R. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612403/
https://www.ncbi.nlm.nih.gov/pubmed/26480871
http://dx.doi.org/10.1186/s12868-015-0208-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612403/
https://www.ncbi.nlm.nih.gov/pubmed/26480871
http://dx.doi.org/10.1186/s12868-015-0208-9

Ejemplares similares